REMARKS

The Notice to Comply mailed April 28, 2003, has been received and reviewed. Responsive thereto, amendments vis-à-vis the patent and in compliance with the format required by 37 C.F.R. § 1.173 are indicated above, with the following changes over the previous version:

In Column 9, para. 3, as the numbers indicating the position of the Gly were mislabeled in the original amendment, the numbers were altered from '6 and 16' to '7 and 17' to bring them into line with the actual sequence.

In Claim 5, the SEQ ID number is changed from '6' to '7' and the number of the Cys residue is altered from '21' to '22.' It should be noted that, with the exception of numbers 1 and 22, where the reference numbering of the amino acid sequence was changed, the proper position of the underlined numbers is in the place of the bracketed removed number such that the number appears properly above the amino acid number it is meant to reference. The amendment to this claim is supported by the disclosure in the patent because the amendment serves only to correct a mistake in the reference numbering that occurred in the original patent. As such, this amendment brings the claim into alignment with the disclosure and the rules of the patent office.

Enclosed is a copy of the Raw Sequence Listing Error Report, along with the following items in connection with the above-referenced application: Statement under 37 C.F.R. §§ 1.821 through 1.825, an underlined paper copy of the sequence listing, and a CRF copy of the sequence listing. It is respectfully submitted that the specification, as originally filed, supports the amendments above and the SEQUENCE LISTING included herein. It is respectfully submitted that this amendment includes no new matter.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: June 3, 2003

Enclosures:

- Copy of Notice to Comply
- Copy of Raw Sequence Listing Error Report
- Statement per 37 C.F.R. §§ 1.821 through 1.825
- Paper copy of SEQUENCE LISTING
- CRF copy of SEQUENCE LISTING
- Petition for extension of time under 37 C.F.R. § 1.136(a)

ACT/djm

SEQUENCE LISTING

<110> Meloen, Robert H
Oonk, Hendrica B
<120>

PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICAL PREPARATION, A METHOD TO IMMUNISE ANIMALS AGAINST THE HORMONE LHRH, AND ANALOGS OF THE LHRH TANDEM REPEAT PEPTIDE AND THEIR USE AS VACCINE

<130> 3516.2US
<140> US 09/876,257
<141> 2001-06-06
<160> 6
<170> PatentIn version 3.1
<210> 1
<211> 10
<212> PRT
<213> Unknown
<220>
<223> Luteinising Hormone Releasing Hormone (LHRH) from the hypothalamus of an undisclosed mammal.

<220>
<221> misc_feature
<222> (-1)..(1)
<223> X at position 1 = pyroglutamic acid

<220>
<221> misc_feature
<222> (10)..(10)
<223> X at position 10 = glycine amide

<400> 1

Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa
1 5 10

<210> 2
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

<221> misc_feature .
<222> (1)..(1) .
<223> X at position 1 = preferably pyroglutamic acid, but can also be glutamine having attached thereto a tail comprising one or more additional amino acids

<220>
<221> misc_feature
<222> (3)..(3)
<223> X at position 3 = tryptophan or formylated tryptophan

<220>
<221> misc_feature
<222> (14)..(14)
<223> X at position 14 = tryptophan or formylated tryptophan

<220>
<221> misc_feature
<222> (10)..(20)
<223> The sequence comprising residues 10-20 may be repeated.

<220>
<221> misc_feature
<222> (21)..(21)
<223> X at position 21 = either nothing or a tail comprising additional amino acid; preferably Cys, the C terminal cysteine being added in connection with a possible coupling of the peptide to a carrier protein.

<400> 2

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly
1 5 10 15

Leu Arg Pro Gly Xaa
20

<210> 3
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

<221> misc_feature
<222> (1)..(1)
<223> X at position 1 = pyroglutamic acid

<220>
<221> misc_feature
<222> (3)..(3)
<223> X at position 3 = tryptophan or N-formyl-Trp

<220>
<221> misc_feature
<222> (13)..(13)
<223> X at position 13 = tryptophan or N-formyl-Trp

<220>
<221> misc_feature
<222> (10)..(19)
<223> The sequence comprising residues 10-19 may be repeated.

<400> 3

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly
1 5 10 15

Leu Arg Pro Gly Cys
20

<210> 4
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>
<221> misc_feature
<222> (1)..(1)
<223> X at position 1 = pyroglutamic acid

<220>
<221> misc_feature
<222> (6)..(6)

<223> X at position 6 = a possible replacement of glycine
by a dextrorotatory amino acid which in addition contains a side chain by whic
h the LHRH tandem unit can be coupled to a carrier compound.

<220>
<221> misc_feature
<222> (16)..(16)
<223> X at position 16 = a possible replacement of
glycine by a dextrorotatory amino acid which in addition contains a side chain by which
the LHRH tandem unit can be coupled to a carrier compound.

<400> 4

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr Xaa
1 5 10 15

Leu Arg Pro Gly Cys
20

<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>
<221> misc_feature
<222> (1)..(1)
<223> X at position 1 = pyroglutamic acid

<220>
<221> misc_feature
<222> (6)..(6)
<223> X at position 6 = Gly or a dextrorotatory amino
acid containing a side chain that allows coupling to a carrier compound.

<400> 5

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys
1 5 10

<210> 6
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>
<221> misc_feature
<222> (21)..(21)
<223> X at position 21 = Cys

<220>
<221> misc_feature
<222> (1)..(21)
<223> The initial cysteine of the peptide comprising
residues 1-21 is joined to the initial cysteine of an identical peptide (residues 2
2-42) to form a dimer.

<400> 6

Cys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr
1 5 10 15

Gly Leu Arg Pro Gly Xaa
20